| Zelefsky, Michael J |
NCT03056638: Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer |
|
|
| Terminated | 3 | 56 | US | Degarelix, stereotactic body radiosurgery (SBRT) | Memorial Sloan Kettering Cancer Center, Ferring Pharmaceuticals, University of Texas Southwestern Medical Center, University of Michigan | Prostate Cancer | 08/23 | 08/23 | | |
NCT05079698: A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer |
|
|
| Recruiting | 1 | 27 | US | 177Lu-PSMA-617, Stereotactic Body Radiotherapy (SBRT) | Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals | Prostate Cancer | 10/25 | 10/25 | | |
| Prato, Stefano Del |
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 780 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Antihyperglycemic medication | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 11/27 | | |
| Solini, Anna |
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight or Obesity, CKD, Type 2 Diabetes | 11/25 | 11/25 | | |
| Masi, Gianluca |
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma |
|
|
| Recruiting | 3 | 200 | Europe, US, RoW | Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma | 05/26 | 08/26 | | |
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy |
|
|
| Completed | 1/2 | 31 | Europe, US | NMS-01940153E | Nerviano Medical Sciences | Unresectable Hepatocellular Carcinoma (HCC) | 01/24 | 08/24 | | |
| Antonelli, Alessandro |
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study |
|
|
| Active, not recruiting | 4 | 313 | Europe, US | Teprotumumab, TEPEZZA, Placebo, Saline Solution | Amgen | Thyroid Eye Disease | 04/26 | 04/26 | | |
| Recruiting | 3 | 112 | Europe, US | ONCOFID P-B (PACLITAXEL-HYALURONIC ACID) | Fidia Farmaceutici s.p.a. | Bladder Carcinoma in Situ (CIS) | 11/25 | 11/27 | | |
Hydeal Cyst, NCT06245603: A Study to Evaluate Efficacy and Safety of ® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | N/A | 200 | Europe | Hydeal Cyst® | Istituto Oncologico Veneto IRCCS, Fidia Farmaceutici s.p.a. | Non-muscle Invasive Bladder Cancer | 12/26 | 06/27 | | |
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC |
|
|
| Active, not recruiting | N/A | 280 | Europe, Canada, US | GAG score | Elypta | Clear Cell Renal Cell Carcinoma | 05/25 | 12/25 | | |
NCT05479422: Optilume Registry for Treatment of Stricture of the Anterior Urethra |
|
|
| Recruiting | N/A | 150 | Europe | | European Association of Urology Research Foundation, Laborie Medical Technologies Inc. | Anterior Urethral Stricture, Male | 08/29 | 08/29 | | |
| Coordinator, Research |
| Recruiting | 4 | 292 | US | Amnion-Intermediate-Chorion, AIC, Amnion-Chorion-Amnion, ACA, Standard of Care, SOC | Cellution Biologics, SerenaGroup, Inc., LifeCell | Diabetic Foot Ulcer, Venous Leg Ulcer | 12/26 | 07/27 | | |
NCT05078827: Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis |
|
|
| Completed | 3 | 458 | US | Test Product (A): Fluorouracil Cream, 5% topical cream, Experimental, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Active Comparator, Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India, Placebo Comparator | Encube Ethicals Pvt. Ltd., CBCC Global Research | Actinic Keratoses | 11/22 | 12/22 | | |
| Completed | 3 | 558 | US | ReMMi-D Digital Therapeutic | Click Therapeutics, Inc. | Migraine, Episodic Migraine, Headache, Headache, Migraine | 05/24 | 05/24 | | |
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study) |
|
|
| Recruiting | 3 | 123 | Europe, Canada, US, RoW | PC945, Placebo | Pulmocide Ltd | Refractory IPA | 03/26 | 04/26 | | |
NCT06004388: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) |
|
|
| Completed | 3 | 110 | US | Click Digital Therapeutic | Click Therapeutics, Inc. | Migraine, Episodic Migraine, Headache, Headache, Migraine | 05/24 | 06/24 | | |
CONVOKE, NCT05838625: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia |
|
|
| Recruiting | 3 | 432 | US | Digital Therapeutic | Click Therapeutics, Inc., Boehringer Ingelheim | Schizophrenia | 06/25 | 07/25 | | |
NCT06067984: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia |
|
|
| Active, not recruiting | 3 | 75 | US | Study App | Click Therapeutics, Inc., Boehringer Ingelheim | Schizophrenia, Negative Symptoms in Schizophrenia | 04/25 | 05/25 | | |
NCT06365437: A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation |
|
|
| Completed | 2 | 33 | Europe | TCD601, Siplizumab, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG | ITB-Med LLC | Kidney Transplantation | 12/24 | 12/24 | | |
| Recruiting | 2 | 25 | Europe, Canada, Japan, US, RoW | nedosiran, DCR-PHXC | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3 | 12/24 | 12/24 | | |
CHASE, NCT05727878: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED |
|
|
| Recruiting | 2 | 90 | US, RoW | KPI-012, KPI-012 Vehicle | Combangio, Inc, Kala Pharmaceuticals, Inc. | Persistent Corneal Epithelial Defect | 03/25 | 10/25 | | |
NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder |
|
|
| Recruiting | 2 | 102 | US | Psilocybin, COMP360 | COMPASS Pathways | Major Depressive Disorder | 10/24 | 11/24 | | |
NCT04270175: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab |
|
|
| Recruiting | 2 | 21 | US | Daratumumab SC, Faspro, Pomalidomide, Dexamethasone | Weill Medical College of Cornell University, Janssen Scientific Affairs, LLC | Amyloid, AL Amyloidosis, Refractory AL Amyloidosis | 12/25 | 12/29 | | |
NCT04803058: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE) |
|
|
| Recruiting | 2 | 18 | US, RoW | TCD601 | ITB-Med LLC | Kidney Transplantation | 03/27 | 03/30 | | |
| Active, not recruiting | 2 | 96 | Europe | TCD601, Placebo | ITB-Med LLC | Diabetes Mellitus, Type 1 | 01/25 | 01/25 | | |
| Recruiting | 2 | 90 | US | TCD601, siplizumab, belatacept, ATG, antithymocyte globulin, TAC, tacrolimus, MPA, mycophenolic acid, Corticosteroids | ITB-Med LLC | Renal Transplantation | 07/25 | 10/26 | | |
NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation |
|
|
| Completed | 2 | 13 | US | TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG | ITB-Med LLC | Kidney Transplantation | 10/23 | 10/23 | | |
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) |
|
|
| Recruiting | 2 | 2190 | US | SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD | NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC | Opioid Use Disorder (OUD) | 07/26 | 12/26 | | |
NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA) |
|
|
| Recruiting | 2 | 18 | US | TCD601 | ITB-Med LLC | Kidney Transplantation | 07/27 | 07/30 | | |
AURORA, NCT06453668: A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients |
|
|
| Active, not recruiting | 1 | 48 | Europe | TCD601, siplizumab | ITB-Med LLC | ALS | 11/26 | 11/26 | | |
| Recruiting | 1 | 15 | US | PBA-0405, PB004.22.0405.aF | Pure Biologics S.A., Presage Biosciences | Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer | 03/25 | 03/25 | | |
MST01-AZN-05, NCT06366451: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC |
|
|
| Recruiting | 1 | 15 | US | Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475 | Presage Biosciences, AstraZeneca | Head and Neck Squamous Cell Carcinoma | 12/24 | 03/25 | | |
| Recruiting | 1 | 155 | US, RoW | OP-1250, Ribociclib, KISQALI®, Alpelisib, PIQRAY®, Everolimus | Olema Pharmaceuticals, Inc., Novartis | Metastatic Breast Cancer, Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer | 05/26 | 06/26 | | |
NCT06798454: Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC) |
|
|
| Recruiting | 1 | 30 | RoW | PVT201, Navacim, Placebo, normal saline, 0.9% NaCl | Parvus Therapeutics, Inc., Avance Clinical Pty Ltd. | Primary Biliary Cholangitis (PBC) | 02/25 | 02/25 | | |
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies |
|
|
| Recruiting | 1 | 15 | US | Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475 | Presage Biosciences, Merck Sharp & Dohme LLC | Solid Tumor | 12/31 | 12/31 | | |
NCT06802328: Treatment Protocol: Intermediate-Size Patient Population Expanded Access |
|
|
| Available | N/A | | US | Foralumab TZLS-401 50 µg | Tiziana Life Sciences LTD | Non-Active Secondary Progressive Multiple Sclerosis | | | | |
NCT06136936: A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia |
|
|
| Completed | N/A | 53 | US | CT-156-C-001 | Click Therapeutics, Inc., Boehringer Ingelheim | Schizophrenia | 01/24 | 02/24 | | |
| Recruiting | N/A | 20 | US | Prototypes of breast shield and Freedom Double Electric Breast Pump | Momtech Inc. | Healthy, Breast Pumping | 09/24 | 11/24 | | |
NCT06136923: An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer |
|
|
| Completed | N/A | 194 | US | CT-100-D-004-A, CT-100-D-004-B | Click Therapeutics, Inc. | Multiple Sclerosis, Lung Cancer, Breast Cancer | 04/24 | 05/24 | | |
| Completed | N/A | 314 | US | FemaSeed Localized Directional Insemination | Femasys Inc. | Infertility, Male Factor | 12/23 | 04/24 | | |
CT-100-D-003, NCT06275659: An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis |
|
|
| Active, not recruiting | N/A | 120 | US | CT-100-004-A, CT-100-004-B | Click Therapeutics, Inc. | Psoriasis, Atopic Dermatitis | 02/24 | 03/24 | | |
NCT05119842: APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study |
|
|
| Recruiting | N/A | 30 | Europe, US | APrevent® VOIS-Implant | APrevent Biotech GmbH | Paralysis, Unilateral, Vocal Cord | 09/25 | 09/26 | | |
Lublin, NCT06217081: 3M™ Topical Tissue Adhesive Versus Commercially Available Tissue Adhesive for the Closure of Lacerations and Incisions |
|
|
| Recruiting | N/A | 452 | US | 3M Topical Tissue Adhesive, Histoacryl® Blue Topical Skin Adhesive | Solventum US LLC, United States Department of Defense, The University of Texas Health Science Center at San Antonio, 3M | Trauma-related Wound, Surgical Incision, Surgical Wound, Laceration | 11/25 | 12/25 | | |
| Recruiting | N/A | 581 | US | | CoMind Technologies Limited, Lindus Health | Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation | 10/25 | 10/25 | | |
| Recruiting | N/A | 50 | US | Pulmonary Valve Replacement Surgery | Autus Valve Technologies, Inc. | Congenital Heart Disease | 08/26 | 02/36 | | |
| Recruiting | N/A | 800 | US | Myriad Matrix™ and Myriad Morcells™ | Aroa Biosurgery Limited | Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury | 01/28 | 01/29 | | |
NCT06770998: A Study of a Novel EEG Neurofeedback System for PTSD Treatment |
|
|
| Not yet recruiting | N/A | 250 | US | EEG-neurofeedback training, Prism training, amyg-EFP training, active Prism training, Sham training, sham Prism training | Foundation for Atlanta Veterans Education and Research, Inc., GrayMatters Health Ltd., Rochester Institute of Technology, New York University Grossman School of Medicine, Atlanta VA Medical Center, Birmingham VA Health Care System, Ralph H. Johnson VA Medical Center, VA Boston Healthcare System, CTP Inc, BioStats Statistical Consulting Ltd, ShareCRF, United States Department of Defense | Stress Disorders, Post-Traumatic | 06/27 | 08/27 | | |
| Active, not recruiting | N/A | 100 | US | Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy | Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs | Cubital Tunnel Syndrome, Nerve Compression, Nerve Injury, Ulnar Neuropathies | 12/25 | 12/25 | | |
| Recruiting | N/A | 573 | US | FemBloc | Femasys Inc. | Contraception | 12/29 | 06/31 | | |
| Recruiting | N/A | 60 | US | Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy | Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs | Nerve Injury, Peripheral Nerve Injuries, Peripheral Nerve Injury Upper Limb, Nerve Palsy | 06/27 | 06/27 | | |
NCT05678530: Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET) |
|
|
| Recruiting | N/A | 400 | Canada, US | | Prolaio | Cardiopulmonary | 06/25 | 06/25 | | |
| Fallahi, Poupak |
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study |
|
|
| Active, not recruiting | 4 | 313 | Europe, US | Teprotumumab, TEPEZZA, Placebo, Saline Solution | Amgen | Thyroid Eye Disease | 04/26 | 04/26 | | |
LIDS, NCT05276063: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) |
|
|
| Active, not recruiting | 2/3 | 90 | Europe, Canada, US | Linsitinib, Placebo | Sling Therapeutics, Inc. | Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto | 10/24 | 09/26 | | |
| Piaggesi, Alberto |
| Recruiting | 2 | 60 | Europe | AUP1602-C, Placebo | Aurealis Oy | Diabetic Foot Ulcer | 10/25 | 10/25 | | |
| Recruiting | N/A | 140 | Europe | Bioactive Glass, Bonalive Granules RDM: 856052; manufacturer code:13120, Bonalive Putty RDM: 855194; manufacturer code:16120, Standard of Care | ASST Ovest Milanese, Hippocrates Research, Bonalive Biomaterials Ltd | Osteomyelitis - Foot | 09/26 | 12/26 | | |
| Terminated | N/A | 21 | Europe | debridement, Offloading, Advanced dressing, Blue Light Photobiomodulation | Emoled, Ospedale San Donato, University of Pisa | Diabetic Foot Ulcer | 07/24 | 07/24 | | |
| Romanelli, Marco |
NCT06239311: Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. |
|
|
| Recruiting | 3 | 212 | Europe, RoW | Methotrexate, Placebo | medac GmbH | Moderate to Severe Atopic Dermatitis | 11/25 | 03/26 | | |
| Recruiting | N/A | 142 | Europe | HM242-Solution, Saline | B. Braun Ltd. Centre of Excellence Infection Control | Venous Leg Ulcer | 10/22 | 12/22 | | |
| Completed | N/A | 83 | Europe | EmoLED, current Standards Of Care | Emoled | Venous Leg Ulcer, Mixed Leg Ulcer | 02/24 | 02/24 | | |
| Ceccarini, Giovanni |
NCT06484868: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy |
|
|
| Recruiting | 4 | 12 | Europe | Metreleptin | Amryt Pharma | Partial Lipodystrophy | 09/27 | 09/27 | | |
| Recruiting | N/A | 100 | Europe, US | Metreleptin | Aegerion Pharmaceuticals, Inc. | Generalised Lipodystrophy, Partial Lipodystrophy | 10/31 | 10/31 | | |
| Elisei, Rossella |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation |
|
|
| Approved for marketing | N/A | | Europe, Japan, US, RoW | Selpercatinib, LOXO-292, LY3527723 | Eli Lilly and Company, Eli Lilly and Company | Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration | | | | |
| Bellini, Massimo |
NCT05016024: Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome. |
|
|
| Completed | N/A | 71 | Europe | Colilen IBS, Placebo | Aboca Spa Societa' Agricola, IQVIA RDS, IQVIA Solutions | Irritable Bowel Syndrome | 02/23 | 02/23 | | |
GIANT, NCT06681012: Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome |
|
|
| Recruiting | N/A | 330 | Europe | Gelsectan®, Placebo | Devintec Sagl | Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D) | 11/25 | 11/25 | | |
| Marazziti, Donatella |
| Active, not recruiting | 3 | 700 | Europe, Canada, US, RoW | Troriluzole, Placebo | Biohaven Pharmaceuticals, Inc. | Obsessive-Compulsive Disorder | 04/25 | 04/25 | | |
| Troisi, Nicola |
| No trials found |
| Mannella, Paolo |
| No trials found |
| Izzetti, Rossana |
| No trials found |
| Zucchi, Alessandro |
| No trials found |
